To explore the clinical research protocol of non-alcoholic fatty liver disease conducive to the clearance of hepatitis B virus combined with intestinal flora

Combined with gut microbiota to evaluate the efficacy of non-alcoholic fatty liver disease for hepatitis B virus clearance: a real-world study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083674

Enrollment

Unknown

Registered

2024-04-30

Start date

2023-09-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHB & NAFLD

Interventions

CHB group :NA

CHB & NAFLD group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years; 2. Meet the diagnostic and treatment criteria of chronic hepatitis B according to guidelines for the prevention and treatment of chronic hepatitis B (version 2022) 3. Meet the diagnostic and treatment criteria of the AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease 4. No antiviral treatment within six months before being selected 5. Volunteer to join this study and sign an informed consent form

Exclusion criteria

Exclusion criteria: 1. Serum anti-HIV positive 2. Liver diseases caused by other causes 3. Pregnant and lactating women 4. Patients who have progressed to liver cirrhosis or hepatocellular carcinoma 5. Subjects who are not suitable to participate in the research according to the researcher's judgment

Design outcomes

Primary

Measure	Time frame
undetectable serum HBV DNA;	—

Secondary

Measure	Time frame
HBsAg loss rate;	—

Countries

China

Contacts

Public ContactMin Liu

The First People's Hospital of Yunnan Province

571552242@qq.com+86 130 9997 3121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026